Navigation Links
GeoVax Labs Reports 2012 First Quarter Financial Results
Date:5/15/2012

of Health (NIH). This compares to $893,002 of grant revenue reported for the same period in 2011. As of March 31, 2012, there is approximately $3.3 million in unused IPCAVD grant funds available for use through August 31, 2012 (the end of the original project period).

Research and development (R&D) expenses were $1,072,354 for the three months ended March 31, 2012, compared with $838,467 for the comparable period in 2011. R&D expenses include direct costs funded by the IPCAVD grant, as well as vaccine manufacturing costs and expenses related to the Phase 1/2 clinical trial, being sponsored by GeoVax, of the Company's therapeutic HIV vaccine. Costs associated with the Phase 2a clinical trial of GeoVax's preventative HIV vaccine, being conducted by the HVTN, are being funded directly by the NIH and are therefore not reflected in GeoVax's financial statements. General and administrative (G&A) expenses were $512,818 and $661,813 for the three months ended March 31, 2012 and 2011, respectively.

GeoVax reported cash balances of $2,240,486 at March 31, 2012, as compared to $1,167,980 at December 31, 2011. Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

About GeoVax's TechnologyGeoVax's unique two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses. GeoVax's DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GeoVax's vaccines are unique in expressing virus-like particles that display the trimeric membrane bound form of the HIV-
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" ... company, is delighted to announce its financial results ... which includes revenue for three months of $2,180,276 ... from advanced wound care product sales for the ... 24% to $1,742,672 compared to $1,400,065 for the ...
(Date:5/29/2015)... 2015  Epic Sciences announced today that the company ... castrate resistant prostate cancer patients, at the 2015 ... Oncology. This application expands the investigational utility of ... platform to characterize circulating tumor cell (CTC) genomic ... have heterogeneous clonal CTC populations harboring separate genetic ...
(Date:5/29/2015)... , May 29, 2015  World-renowned prostate surgeon and New ... on the benefit of MR/Ultrasound Fusion-Guided Biopsy for ... Prostate Cancer Center at Lenox Hill Hospital is ... System in New York City . We,ve ... risk prostate cancers. The use of an MRI makes for ...
Breaking Medicine Technology:Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
(Date:5/29/2015)... North Carolina (PRWEB) May 29, 2015 ... confirmed that the newest Red Hot & Blue restaurant at ... business on Thursday, May 7, 2015. “The Red Hot & ... center for 18 years, but we have moved to a ... are now in the middle of all the activities on ...
(Date:5/29/2015)... May 29, 2015 Johnson & ... a confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement ... due to his use of the antipsychotic medication. ... selected for the third bellwether trial to involve ... litigation underway in Pennsylvania’s Philadelphia Court of Common ...
(Date:5/29/2015)... May 29, 2015 World Patent Marketing, ... announces that it has signed a 10 year licensing ... that aims to let people learn about any topic ... time. , "This is an exciting day for World ... Scott J. Cooper, CEO and Creative Director of World ...
(Date:5/29/2015)... May 29, 2015 The print component ... a circulation of approximately 250,000 and an estimated readership ... a vast social media strategy, and across a network ... the digital version of the campaign, click here. ... print publication. Inside, the actress, model and producer details ...
(Date:5/29/2015)... May 29, 2015 The campaign focuses ... as a number of specific concerns within, including the ... and mental health in the workplace. We are encouraged ... The campaign also brings special focus to people living ... speak up and seek help from healthcare professionals and ...
Breaking Medicine News(10 mins):Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 3Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 4Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5Health News:Mediaplanet Brings Activism to Those Living with Mental Illness in Bew “Mental Health Awareness” Campaign 2
... Regions, These Markets Remain Stable, According to New ... HealthLeaders-InterStudy, a leading provider of managed care ... many regions of the country have halted because ... in Buffalo, N.Y., and Baton Rouge, La., are ...
... Calif., Jan. 26 Doctors at the,Northwoods Cancer ... patients,using new RapidArc radiotherapy technology from Varian Medical ... a retired machinist fighting prostate cancer, is,among the ... speed and accuracy of,RapidArc, which delivers image-guided intensity-modulated ...
... Jan. 26 ChromaDex Corporation, (OTC Bulletin Board: ... contract research, announced today that Nutrition Business Journal, ... care magazine, selected the Company as one of ... its achievement in setting stevia standards as part ...
... will add new technology to help ORBIS train doctors ... ORBIS International , a nonprofit ... donated PASCAL photocoagulator as part of a new partnership ... to treat a variety of retinal diseases, PASCAL dramatically ...
... Jan. 26 FluoroPharma Inc., a company ... Positron Emission Tomography (PET) market, announced today ... Office issued U.S. Patent No. 7,438,891, covering ... F18 labeled 2-fluorodeoxy-D-glucose (FDG). This patent, exclusively ...
... N.J., Jan. 26 Quest Diagnostics Incorporated (NYSE: ... of diagnostic testing, information and services, announced that ... in share repurchases. The company had approximately 190 ... 2008."This repurchase program demonstrates confidence in our performance ...
Cached Medicine News:Health News:Hospital Expansions in Buffalo, N.Y., and Baton Rouge, La., Contribute to Recession Resilience 2Health News:Hospital Expansions in Buffalo, N.Y., and Baton Rouge, La., Contribute to Recession Resilience 3Health News:A Fast, New Cancer Fighting Tool Is Now Available in the Houston Area: RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 2Health News:A Fast, New Cancer Fighting Tool Is Now Available in the Houston Area: RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 3Health News:ChromaDex Awarded Nutrition Business Journal Scientific Achievement 2Health News:ORBIS International Receives Donated PASCAL(R) Photocoagulator From OptiMedica 2Health News:ORBIS International Receives Donated PASCAL(R) Photocoagulator From OptiMedica 3Health News:ORBIS International Receives Donated PASCAL(R) Photocoagulator From OptiMedica 4Health News:FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG 2Health News:Quest Diagnostics' Board Authorizes $500 Million in Share Repurchases 2
... 3Z slit lamp is designed to for ... ready slit lamp offers the popular horizontal ... to the ReSeeVit family of slit lamps ... market to capture clear, crisp digital images ...
... system combines continuous access, random ... a broad testing menu. AxSYM ... clinical laboratories to process a ... as well as adding tests ...
... an automated, multiparametric immunoassay system. ... stores the calibration in the ... cost-per-patient result. Plus, ease ... labor cost is also optimized. ...
... AIA-1800 is the newest and most advanced ... The AIA-1800 launches with a full ... markers, thyroid, reproductive, cardiac, and anemia assays. ... throughput, bar-coded primary tube sampling, auto dilution, ...
Medicine Products: